Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Table 2 Treatment history of enrolled patients

	L (n = 13)		L + R (n = 11)		L + other (n = 34)		Overall (N = 58)
	No.	%	No.	%	No.	%	No.	%
No. of prior antilymphoma treatment regimens
Median	4		3		4		4
Range	3–7		2–8		1–13		1–13
No. of prior antilymphoma therapies
1	0	0	0	0	1	3	1	2
2	0	0	4	36	2	6	6	10
3	5	38	3	27	10	29	18	31
≥ 4	8	62	4	36	21	62	33	57
Missing	0	0	0	0	0	0	0	0
Type of ibrutinib treatment
Combination regimen	1	8	1	9	10	29	12	21
Monotherapy	12	92	10	91	24	71	46	79
Ibrutinib status at study inclusion
Relapse/PD	6	46	2	18	15	44	23	40
Refractory	2	15	8	73	15	44	25	43
Intolerant	3	23	0	0	3	9	6	10
Missing	2	15	1	9	1	3	4	7
Duration of ibrutinib treatment, months
Median	4.8		3.9		4.3		4.3
Range	1.2–13.9		2.0–16.6		0.5–47.6		0.5–47.6
Best response on ibrutinib
CR	2	15	0	0	6	18	8	14
PR	5	38	2	18	11	32	18	31
SD	0	0	1	9	0	0	1	2
Relapse/PD	5	38	8	73	15	44	28	48
Unknown	1	8	0	0	2	6	3	5
Primary reason for ibrutinib discontinuation
Lack of efficacy	9	69	11	100	31	91	51	88
Toxicity to ibrutinib	3	23	0	0	2	6	5	9
Toxicity attribution unknown	0	0	0	0	1	3	1	2
Completed ibrutinib treatment	1	8	0	0	0	0	1	2
Time from end of last dose of ibrutinib to first dose of lenalidomide, weeks^a
Median	1.4		0.4		1.3		1.3
Range	0.1–7.4		0.1–21.7		0.1–16.8		0.1–21.7

CR complete response, L lenalidomide, L + R lenalidomide plus rituximab, PD progressive disease, PR partial response, SD stable disease
^aTime from last dose of ibrutinib to first dose of lenalidomide (weeks) is calculated as (lenalidomide first dose date − end date of ibrutinib + 1)/7

ISSN: 1756-8722